Who Generates Higher Gross Profit? GSK plc or Bio-Techne Corporation

GSK vs. Bio-Techne: A Decade of Profit Comparison

__timestampBio-Techne CorporationGSK plc
Wednesday, January 1, 201425141100015683000000
Thursday, January 1, 201530727700015070000000
Friday, January 1, 201633665900018599000000
Sunday, January 1, 201737454100019844000000
Monday, January 1, 201843214300020580000000
Tuesday, January 1, 201947349100021891000000
Wednesday, January 1, 202048319400022395000000
Friday, January 1, 202163285000022511000000
Saturday, January 1, 202275649600019770000000
Sunday, January 1, 202376981500021763000000
Monday, January 1, 2024769725000
Loading chart...

Unleashing the power of data

A Tale of Two Giants: GSK plc vs. Bio-Techne Corporation

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding who leads in profitability is crucial. Over the past decade, GSK plc has consistently outperformed Bio-Techne Corporation in terms of gross profit. From 2014 to 2023, GSK's gross profit has been approximately 40 times higher than that of Bio-Techne, showcasing its dominance in the industry. Notably, GSK's peak gross profit in 2021 was around $22.5 billion, while Bio-Techne's highest was about $770 million in 2023. Despite Bio-Techne's impressive growth, with a 206% increase in gross profit from 2014 to 2023, GSK's robust financial performance underscores its strong market position. However, the data for 2024 is incomplete, leaving room for speculation on future trends. This comparison highlights the dynamic nature of the industry and the importance of strategic growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025